Managed Access Programs for ABL001, Asciminib

Exclusion Criteria

• •4. There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
• •5. The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).
• •6. Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.
• •7. Managed Access provision is allowed per local laws/regulations